Method for making multispecific antibodies having heteromultimeric and common components

• US 7,951,917 B1
• Filed: 03/07/2000
• Issued: 05/31/2011
• Est. Priority Date: 05/02/1997
• Status: Expired due to Fees

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Carter, Paul J., Arathoon, W. Robert, Merchant, Anne M., Presta, Leonard G.
• Primary Examiner(s): Harris; Alana M
• Assistant Examiner(s): Holleran; Anne L
• Application Number:
  US09/520,130
• Time in Patent Office: 4,102 Days
• Field of Search: 530/387.3, 424/130.1, 424/133.1, 424/134.1, 424/135.1, 424/136.1, 424/138.1, 424/141.1, 424/152.1, 424/155.1, 424/156.1
• US Class Current: 530/387.3
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/46 Hybrid immunoglobulins hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide. The method allows for the enhanced formation of the desired heteromultimer relative to undesired heteromultimers and homomultimers.

Claims

1. A multispecific antibody comprising four polypeptides, wherein a first and a second of said polypeptides each comprise a heavy chain constant domain and a heavy chain variable domain, and a third and a fourth of said polypeptides are each common light chains that are identical to each other, wherein said first polypeptide and said third polypeptide form a binding domain that binds a first antigen, and wherein said second polypeptide and said fourth polypeptide form a binding domain that binds a different antigen, and wherein said first polypeptide and said second polypeptide dimerize to form a multispecific antibody, wherein the multispecific antibody is an IgG, IgE or IgD antibody.

2. The multispecific antibody of claim 1, wherein the first polypeptide further comprises a first multimerization domain, and the second polypeptide further comprises a second multimerization domain, and wherein the first and second polypeptides dimerize by interaction of the first and second multimerization domains to form a multispecific antibody.

3. The multispecific antibody of claim 2, wherein the multimerization domains of the first and second polypeptide interact at an amino acid side chain protuberance of one of the first and second polypeptides and an amino acid side chain cavity of the other polypeptide.

4. The multispecific antibody of claim 2, further comprising a non-naturally occurring disulfide bond between the first and second polypeptide.

5. The multispecific antibody of claim 4, wherein the multimerization domain is at least a part of a C_H3 domain region of an antibody constant domain, and the non-naturally occurring disulfide bond is between the C_H3 multimerization domains of the first and second polypeptides.

6. A composition comprising the multispecific antibody of claim 1 and a carrier.

7. A multispecific antibody comprising two heteromeric polypeptides and two light chains wherein:

(a) the first heteromeric polypeptide comprises a first heavy chain variable domain and a first multimerization domain; and

(b) the second heteromeric polypeptide comprises a second heavy chain variable domain and a second multimerization domain; and

wherein the two light chains have an amino acid sequence identity of 100%, and the first and second heteromeric polypeptides dimerize by interaction of the first and second multimerization domains to form a multispecific antibody, wherein the multispecific antibody is an IgG, IgE or IgD antibody.

8. The multispecific antibody of claim 7, wherein the first multimerization domain has a protuberance and the second multimerization domain has a cavity, and wherein the protuberance is positionable in the cavity.

9. The multispecific antibody of claim 8 further comprising a non-naturally occurring disulfide bond between the first and second heteromeric polypeptides.

10. The multispecific antibody of claim 7, further comprising a non-naturally occurring disulfide bond between the first and second heteromeric polypeptides.

11. The multispecific antibody of claim 10, wherein the multimerization domains comprise a part of a C_H3 domain of an antibody constant domain, and the non-naturally occurring disulfide bond is between the C_H3 multimerization domains of the first and second heteromeric polypeptides.

12. A composition comprising the multispecific antibody of claim 7 and a carrier.